Luca De Carolis - Concepedia

Author

Luca De Carolis

University of Perugia

Also Known As

L. De Carolis, Lilia De Carolis, Lilia de Carolis, Luca De Carolis, Luca de Carolis

Publications

857

Citations

H-Index

Concepts

All Affiliations

University of Perugia Sapienza University of Rome Università degli Studi del Piemonte Orientale “Amedeo Avogadro”University of Verona Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia

About

Luca De Carolis is an author at University of Perugia specializing in pharmacotherapy, oncology, and medicine.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	2	2	63
2	Pharmacology	2	2	63
3	Cancer Therapeutics	2	2	63
4	Immunology	1	1	19
5	Molecular Medicine	1	1	19

Luca De Carolis

Publications

808

Citations

H-Index

Page 1

	Year	Citations
Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia Enrico Tiacci, Jae H. Park, Luca De Carolis, New England Journal of Medicine	2015	331
Whole-exome sequencing identifies somatic mutations of BCOR in acute myeloid leukemia with normal karyotype Enrico Tiacci, Antony B. Holmes, Alexander Kohlmann, Blood	2011	248
Vemurafenib plus Rituximab in Refractory or Relapsed Hairy-Cell Leukemia Enrico Tiacci, Luca De Carolis, Edoardo Simonetti, New England Journal of Medicine	2021	116
Safety and efficacy of the BRAF inhibitor dabrafenib in relapsed or refractory hairy cell leukemia: a pilot phase-2 clinical trial Enrico Tiacci, Luca De Carolis, Edoardo Simonetti, Leukemia Hematological MalignancyOncologyMedicinePharmacotherapyAnti-cancer Agent	2021	44
How I treat refractory/relapsed hairy cell leukemia with BRAF inhibitors Brunangelo Falini, Luca De Carolis, Enrico Tiacci Blood	2022	24
THE BRAF INHIBITOR VEMURAFENIB PLUS RITUXIMAB PRODUCES A HIGH RATE OF DEEP AND DURABLE RESPONSES IN RELAPSED/REFRACTORY HAIRY CELL LEUKEMIA: UPDATED RESULTS OF A PHASE‐2 TRIAL Enrico Tiacci, Luca De Carolis, Edoardo Simonetti, Hematological Oncology ImmunologyHcl CellsPharmacotherapyImmunotherapyMyeloid Neoplasia	2019	19
Distribution Systems as Catalysts for Energy Transition Embedding Flexibility in Large-Scale Applications Gianni Celli, Giuditta Pisano, Simona Ruggeri, IEEE Access	2024	16
Efficacy and Safety of the BRAF Inhibitor Vemurafenib in Hairy Cell Leukemia Patients Refractory to or Relapsed after Purine Analogs: A Phase-2 Italian Clinical Trial Enrico Tiacci, Luca De Carolis, Pier Luigi Zinzani, Blood	2014	10

Page 1